High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Abstract Text:

Susan M Talbot,Cathryn Rankin,Robert N Taub,Stanley P Balcerzak,Nirmala Bhoopalam,Robert A Chapman,Laurence H Baker,Edward L Middleman,Karen H Antman,

BACKGROUND: The current study was conducted to assess the activity and toxicity of high-dose ifosfamide and mesna with recombinant human granulocyte-colony-stimulating factor (rhG-CSF), given in an outpatient setting, in the treatment of patients with unresectable malignant mesothelioma. METHODS: Between September 1994 and September 1996, 41 patients with histologically verified, unresectable malignant mesothelioma were registered, 38 of whom were analyzable (2 were ineligible and 1 was nonanalyzable). Patients received intravenous ifosfamide at a dose of 2.8 g/m2 over 3 hours (total dose of 14 g/m2), plus mesna at a dose of 0.56 g/m2 prior to and at 4 hours and 8 hours after ifosfamide infusion daily for 5 days every 21 days. rhG-CSF at a dose of 5 microg/kg/day was administered subcutaneously on days 6-15. RESULTS: Response assessment could be determined adequately in 21 patients. Two patients obtained responses; 1 was a confirmed partial response (3%; 95% confidence interval [95% CI], 0-14%) and 1 was an unconfirmed response (3%; 95% CI, 5-14%). Eleven patients had stable disease (29%), 7 patients developed disease progression (18%), 1 patient had an early death (3%), and 17 patients had inadequate assessment (45%). At the time of last follow-up, 36 of the 38 eligible patients had developed disease progression, with a median progression-free survival of 5 months (95% CI, 3-7 months) and 34 patients had died with a median survival of 7 months (95% CI, 6-9 months). Twenty-four patients (63%) and 7 patients (18%), respectively, had Grade (according to Southwestern Oncology Group Toxicity Criteria) 4 hematologic toxicities and Grade 4 nonhematological toxicities. There was one treatment-related death, the result of infection, pulmonary edema, and renal failure. CONCLUSIONS: This regimen demonstrated a low overall objective response rate with substantial toxicity, and in the opinion of the authors does not warrant further investigation in the treatment of patients with unresectable malignant mesothelioma.

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Publishing Authors By Initials

SM Talbot,C Rankin,RN Taub,SP Balcerzak,N Bhoopalam,RA Chapman,LH Baker,EL Middleman,KH Antman,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Cancer

VOLUME: 98

Page Numbers: 331-6

Journal Abbreviation: Cancer

ISSN: 0008-543X

DAY: 15

MONTH: Jul

YEAR: 2003

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 374236

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Information

Substance Name: Ifosfamide

Registry Number: 3778-73-2

Grant and Affiliation Information for High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.

AFFILIATION: Division of Medical Oncology, Columbia University, College of Physicians and Surgeons, New York, New York, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA76447

ACRONYM: CA

MEDLINETA: Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor recombinant human G-CSF in patients with unresectable malignant mesothelioma Related Publications

• A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.
• Coronary Care Medicine: It's Not Your Father's CCU Anymore.
• Diabetes and mortality following acute coronary syndromes.
• Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes.
• Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25.
• Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
• High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
• Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
• Is fondaparinux safer than enoxaparin for patients undergoing percutaneous coronary intervention?
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.
• The specialty of emergency medicine: needed now more than ever before.
• Time is muscle translation into practice.